Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 3, 2013, Pages 613-624

  Datta, Mridul ^a   Schwartz, Gary G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bone mineral density; Breast cancer; Calcium; Osteoporosis; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTRADIOL; ESTRONE; PLACEBO; TAMOXIFEN; VITAMIN D;

BONE DENSITY; BREAST CANCER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIETARY REFERENCE INTAKE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ESTROGEN ACTIVITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; OSTEOLYSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

BONE MINERAL DENSITY; BREAST CANCER; CALCIUM; OSTEOPOROSIS; VITAMIN D;

BONE DENSITY; BREAST NEOPLASMS; CALCIUM; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; ESTROGENS; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; VITAMIN D;

EID: 84888286929     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.07.002     Document Type: Review

References (104)

1. Brown S., Guise T. Cancer-associated bone disease. Current Osteoporosis Reports 2007, 5:120-127.
2. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Critical Reviews in Oncology/Hematology 2009, 69:73-82.
3. Hirbe A., Morgan E.A., Uluçkan Ö., Weilbaecher K. Skeletal complications of breast cancer therapies. Clinical Cancer Research 2006, 12:6309s-6314s.
4. Kanis J.A., McCloskey E.V., Powles T., Paterson A.H.G., Ashley S., Spector T. A high incidence of vertebral fracture in women with breast cancer. British Journal of Cancer 1999, 79:1179-1181.
5. Edwards B.J., Raisch D.W., Shankaran V., et al. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clinical Cancer Research 2011, 17:560-568.
6. Brenneman S.K., Barrett-Connor E., Sajjan S., Markson L.E., Siris E.S. Impact of recent fracture on health-related quality of life in postmenopausal women. Journal of Bone and Mineral Research 2006, 21:809-816.
7. Hagino H., Nakamura T., Fujiwara S., Oeki M., Okano T., Teshima R. Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporosis International 2009, 20:695-702.
8. Hallberg I., Rosenqvist A.M., Kartous L., Löfman O., Wahlström O., Toss G. Health-related quality of life after osteoporotic fractures. Osteoporosis International 2004, 15:834-841.
9. Abrahamsen B., van Staa T., Ariely R., Olson M., Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporosis International 2009, 20:1633-1650.
10. Panula J., Pihlajamäki H., Mattila V.M., et al. Mortality and cause of death in hip fracture patients aged 65 or older - a population-based study. BMC Musculoskeletal Disorders 2011, 12:105-110.
11. Datta M., Schwartz G.G. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review. Oncologist 2012, 17:1171-1179.
12. Ross A.C., Abrams S.A., Aloia J.F., et al. Dietary reference intakes for calcium and vitamin D 2010, National Academy of Sciences, Washington, DC.
13. Institute of Medicine Dietary reference intakes for calcium and vitamin D 2011, The National Academies Press, Washington, DC.
14. Centers for Disease Control and Prevention About the National Health and Nutrition Examination Survey 2011, Retrieved October 18, 2011, from http://www.cdc.gov/nchs/nhanes/about_nhanes.htm.
15. Bailey R.L., Dodd K.W., Goldman J.A., et al. Estimation of total usual calcium and vitamin D intakes in the United States. The Journal of Nutrition 2010, 140:817-822.
16. Kalkwarf H.J., Khoury J.C., Lanphear B.P. Milk intake during childhood and adolescence, adult bone density, and osteoporotic fractures in us women. The American Journal of Clinical Nutrition 2003, 77:257-265.
17. Zhu K., Prince R.L. Calcium and bone. Clinical Biochemistry 2012, 45:936-942.
18. Lips P., Bouillon R., Van Schoor N.M., et al. Reducing fracture risk with calcium and vitamin D. Clinical Endocrinology (Oxford) 2010, 73:277-285.
19. Moyer V.A. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2013, 10.7326/0003-4819-158-9-201305070-00603.
20. Zahrani A.A., Levine M.A. Primary hyperparathyroidism. Lancet 1997, 349:1233-1238.
21. Brown E.M. Physiology of calcium homeostasis. The parathyroids: basic and clincal concepts 2001, 167-182. Academic Press, San Diego, CA. 2nd ed. J.P. Bilezikian, R. Marcus, M.A. Levine (Eds.).
22. Mann G.B., Kang Y.C., Brand C., Ebeling P.R., Miller J.A. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. Journal of Clinical Oncology 2009, 27:3605-3610.
23. Eroles P., Bosch A., Alejandro Pérez-Fidalgo J., Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treatment Reviews 2012, 38:698-707.
24. Puhalla S., Bhattacharya S., Davidson N.E. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Molecular Oncology 2012, 6:222-236.
25. National Comprehensive Cancer Network Guidelines for treatment of cancer by site: breast cancer v3 2012, Retrieved October 29, 2012, from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
26. Burger H.G. Physiology and endocrinology of the menopause. Medicine (Baltimore) 2006, 34:27-30.
27. Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. Production and actions of estrogens. The New England Journal of Medicine 2002, 346:340-352.
28. Miller W.R. Biological rationale for endocrine therapy in breast cancer. Best Practice & Research: Clinical Endocrinology & Metabolism 2004, 18:1-32.
29. Bulun S.E., Zeitoun K., Sasano H., Simpson E.R. Aromatase in aging women. Seminars in Reproductive Endocrinology 1999, 17:349-358.
30. Osborne C.K. Tamoxifen in the treatment of breast cancer. The New England Journal of Medicine 1998, 339:1609-1618.
31. Osborne C.K., Zhao H., Fuqua S.A.W. Selective estrogen receptor modulators: structure, function, and clinical use. Journal of Clinical Oncology 2000, 18:3172-3186.
32. Powles T.J., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology 1996, 14:78-84.
33. Vehmanen L., Elomaa I., Blomqvist C., Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. Journal of Clinical Oncology 2006, 24:675-680.
34. Krishnan A.V., Swami S., Peng L., Wang J., Moreno J., Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010, 151:32-42.
35. Hadji P., Gnant M., Body J.J., et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?. Cancer Treatment Reviews 2012, 38:798-806.
36. Hiscox S., Davies E.L., Barrett-Lee P. Aromatase inhibitors in breast cancer. Maturitas 2009, 63:275-279.
37. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. Journal of Clinical Oncology 2008, 26:1051-1057.
38. The Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. The Lancet Oncology 2008, 9:45-53.
39. Rabaglio M., Sun Z., Price K.N., et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology 2009, 20:1489-1498.
40. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., Adams J.E. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). Journal of Bone and Mineral Research 2006, 21:1215-1223.
41. American Society of Clinical Oncology Clinical practice guidelines: breast cancer 2012, Retrieved August 20, 2012, from http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/Breast+Cancer.
42. Agency for Healthcare Research and Quality National guideline clearinghouse 2011, Retrieved September 2, 2011, from http://www.guideline.gov/.
43. Body J., Bergmann P., Boonen S., et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club. Osteoporosis International 2007, 18:1439-1450.
44. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology 2003, 21:4042-4057.
45. Rizzoli R., Body J., De Censi A., Reginster J., Piscitelli P., Brandi M. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporosis International 2012, 1-10. 10.1007/s00198-011-1870-0.
46. Reid D.M., Doughty J., Eastell R., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treatment Reviews 2008, 34(Suppl. 1):S3-S18.
47. Hadji P., Aapro M.S., Body J.J., et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Annals of Oncology 2011, 22:2546-2555.
48. BreastCancer.org 2012, Retrieved August 15, 2012, from http://www.breastcancer.org.
49. Hartsock M.A. Guide to understanding bone health 2010, 1-29. Living Beyond Breast Cancer, Haverford, PA. 1st ed. Living Beyond Breast Cancer (Ed.).
50. Susan G. Komen for the Cure 2012, September 11, 2012, from http://ww5.komen.org/.
51. Young Survival Coalition Taking care of them bones. Living your best: quality of life 2012, Retrieved September 11, 2012, from http://www.youngsurvival.org/breast-cancer-in-young-women/living-with-breast-cancer/quality-of-life#null.
52. Llombart A., Frassoldati A., Paija O., et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clinical Breast Cancer 2012, 12:40-48.
53. Shapiro C.L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of Clinical Oncology 2001, 19:3306-3311.
54. Waltman N., Twiss J., Ott C., et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporosis International 2010, 21:1361-1369.
55. Cohen A., Fleischer J.B., Johnson M.K., et al. Prevention of bone loss after withdrawal of tamoxifen. Endocrine Practice 2008, 14:162-167.
56. Kim J., Ahn J.-H., Jung K., et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean cancer study group (KCSG-BR06-01). Breast Cancer Research and Treatment 2011, 125:99-106.
57. Shapiro C.L., Halabi S., Hars V., et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. European Journal of Cancer 2011, 47:683-689.
58. Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. Journal of Clinical Oncology 2008, 26:4739-4745.
59. Hershman D.L., McMahon D.J., Crew K.D., et al. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. The Journal of Clinical Endocrinology and Metabolism 2010, 95:559-566.
60. Hines S.L., Mincey B.A., Sloan J.A., et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. Journal of Clinical Oncology 2009, 27:1047-1053.
61. Fuleihan G.E.-H., Salamoun M., Mourad Y.A., et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism 2005, 90:3209-3214.
62. Prieto-Alhambra D., Servitja S., Javaid M., et al. Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study. Breast Cancer Research and Treatment 2012, 133:1159-1167.
63. Sergi G., Pintore G., Falci C., et al. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. Journal of Bone and Mineral Metabolism 2012, 30:461-467.
64. Safra T., Bernstein-Molho R., Greenberg J., et al. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology 2011, 81.
65. Rastelli A., Taylor M., Gao F., et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Research and Treatment 2011, 129:107-116.
66. Markopoulos C., Tzoracoleftherakis E., Polychronis A., et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the arbi prospective clinical trial. Breast Cancer Research 2010, 12:1-12.
67. Van Poznak C., Hannon R.A., Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. Journal of Clinical Oncology 2010, 28:967-975.
68. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. Journal of Clinical Oncology 2008, 26:4875-4882.
69. Greenspan S.L., Brufsky A., Lembersky B.C., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. Journal of Clinical Oncology 2008, 26:2644-2652.
70. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clinical Cancer Research 2008, 14:6336-6342.
71. Sawka A.M., Ioannidis G., Papaioannou A., et al. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?. Journal of Obstetrics and Gynaecology Canada 2005, 27:759-764.
72. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update. Circulation 2012, 125:e2-e220.
73. Patnaik J., Byers T., DiGuiseppi C., Dabelea D., Denberg T. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Research 2011, 13:R64.
74. Wellons M., Ouyang P., Schreiner P.J., Herrington D.M., Vaidya D. Early menopause predicts future coronary heart disease and stroke: the multi-ethnic study of atherosclerosis. Menopause 2012, 19:1081-1087.
75. Schmitz K.H., Prosnitz R.G., Schwartz A.L., Carver J.R. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 2012, 118:2270-2276.
76. Yeh E.T.H., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. Journal of the American College of Cardiology 2009, 53:2231-2247.
77. Hernandez R.K., Sørensen H.T., Pedersen L., Jacobsen J., Lash T.L. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism. Cancer 2009, 115:4442-4449.
78. Amir E., Seruga B., Niraula S., Carlsson L., Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute 2011, 103:1299-1309.
79. Xiao Q., Murphy R.A., Houston D.K., Harris T.B., Chow W., Park Y. Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health - AARP diet and health study. JAMA Internal Medicine 2013, 173:639-646.
80. Bolland M.J., Grey A., Avenell A., Gamble G.D., Reid I.R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the women's health initiative limited access dataset and meta-analysis. British Medical Journal 2011, 342. 10.1136/bmj.d2040.
81. Li K., Kaaks R., Linseisen J., Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and nutrition study (EPIC-Heidelberg). Heart 2012, 98:920-925.
82. Bolland M.J., Barber P.A., Doughty R.N., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. British Medical Journal 2008, 336:262-266.
83. Michaëlsson K., Melhus H., Lemming E.W., Wolk A., Byberg L. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. British Medical Journal 2013, 346. 10.1136/bmj.f228.
84. Lewis J.R., Calver J., Zhu K., Flicker L., Prince R.L. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. Journal of Bone and Mineral Research 2011, 26:35-41.
85. Manson J.E., Allison M.A., Carr J.J., et al. Calcium/vitamin D supplementation and coronary artery calcification in the women's health initiative. Menopause 2010, 17:683-691.
86. Bolland M.J., Avenell A., Baron J.A., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. British Medical Journal 2010, 341. 10.1136/bmj.c3691.
87. Samelson E.J., Booth S.L., Fox C.S., et al. Calcium intake is not associated with increased coronary artery calcification: the Framingham study. The American Journal of Clinical Nutrition 2012, 96:1274-1280.
88. Heine G.H., Nangaku M., Fliser D. Calcium and phosphate impact cardiovascular risk. European Heart Journal 2013, 34:1112-1121.
89. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International 2005, 68:1815-1824.
90. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International 2002, 62:245-252.
91. Hunt C.D., Johnson L.K. Calcium requirements: new estimations for men and women by cross-sectional statistical analyses of calcium balance data from metabolic studies. The American Journal of Clinical Nutrition 2007, 86:1054-1063.
92. Wang L., Manson J.E., Sesso H.D. Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. American Journal of Cardiovascular Drugs 2012, 12:105-116.
93. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. Journal of Clinical Oncology 2006, 24:3629-3635.
94. Straub D.A. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutrition in Clinical Practice 2007, 22:286-296.
95. Heaney R.P. The importance of calcium intake for lifelong skeletal health. Calcified Tissue International 2002, 70:70-73.
96. Wang L., Manson J.E., Song Y., Sesso H.D. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Annals of Internal Medicine 2010, 152:315-323.
97. Brøndum-Jacobsen P., Benn M., Jensen G.B., Nordestgaard B.G. 25-Hydroxyvitamin D levels and risk of ischemic heart disease, myocardial infarction, and early death. Arteriosclerosis, Thrombosis, and Vascular Biology 2012, 32:2794-2802.
98. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
99. Vacek J.L., Vanga S.R., Good M., Lai S.M., Lakkireddy D., Howard P.A. Vitamin D deficiency and supplementation and relation to cardiovascular health. The American Journal of Cardiology 2012, 109:359-363.
100. Dawson-Hughes B., Dallal G.E., Krall E.A., Sadowski L., Sahyoun N., Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. The New England Journal of Medicine 1990, 323:878-883.
101. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. The New England Journal of Medicine 1997, 337:670-676.
102. Reid I.R., Ames R.W., Evans M.C., Gamble G.D., Sharpe S.J. Effect of calcium supplementation on bone loss in postmenopausal women. The New England Journal of Medicine 1993, 328:460-464.
103. Aloia J.F., Chen D.-G., Yeh J.K., Chen H. Serum vitamin D metabolites and intestinal calcium absorption efficiency in women. The American Journal of Clinical Nutrition 2010, 92:835-840.
104. Riihimäki M., Thomsen H., Brandt A., Sundquist J., Hemminki K. Death causes in breast cancer patients. Annals of Oncology 2012, 23:604-610.